Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.64 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.64 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27545187 | 0.85 | KMT2A (0.74) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL27743845 | 0.83 | KMT2A (0.71) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL917665 | 0.82 | KMT2A (0.70) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL13994872 | 0.82 | KMT2A (1.00) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL4207187 | 0.82 | CACNA2D1 (0.72) | CACNA2D1CACNA1BCACNB1CACNA1CCNR1 | |
| SCHEMBL4775597 | 0.81 | KMT2A (0.64) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL4778556 | 0.81 | CACNA2D1 (0.72) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL31350986 | 0.81 | MAOB (1.00) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL3919536 | 0.80 | OPRM1 (0.78) | KMT2AMAOBNPSR1MAPTKDM4E | |
| SCHEMBL8175607 | 0.80 | OPRM1 (0.78) | KMT2AMAOBNPSR1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326840-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7304053-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-6809093-B2 | DRUG RESISTANCE THERAPY | H. LEE MOFFITT CANCER & RESEARCH INSTITUTE, INC. | 2004-10-26 | — | — | US | disclosed |
| US-6693099-B2 | FOR INHIBITING TRANSPORT PROTEIN; THERAPY | THE PROCTER & GAMBLE COMPANY | 2004-02-17 | — | — | US | disclosed |
| EP-1326834-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | The Procter & Gamble Company (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326840-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-09-12 | — | — | US | disclosed |
| US-20020123498-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS OPTIONALLY CONTAINING A QUINOLYL MOIETY FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-09-05 | — | — | US | disclosed |
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | disclosed |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020115659-A1 | Compounds having heterocyclic groups containing two nitrogen atoms for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-22 | — | — | US | disclosed |
| WO-2002032868-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032874-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032871-A2 | COMPOUNDS AND METHODS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115659-A1 | Compounds having heterocyclic groups containing two nitrogen atoms for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | KMT2A 3453/4885MAOB 735/4885NPSR1 1560/4885 |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | ABCC1, SLC11A2, ABCB1 | KMT2A 2186/4885MAOB 744/4885NPSR1 1566/4885 |
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | KMT2A 3528/4885MAOB 935/4885NPSR1 3051/4885 |
| US-20020123498-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS OPTIONALLY CONTAINING A QUINOLYL MOIETY FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCC5 | KMT2A 3105/4885MAOB 1615/4885NPSR1 3381/4885 |
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCG2 | KMT2A 3107/4885MAOB 468/4885NPSR1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.